1Melief C J,Toes R E,Medema J P,et al.Strategies for immunotherapy of cancer[J].Adv Immunol,2000,75:235-282.
2Jager E,Jager D,Knuth A.Antigen-specific immunotherapy and cancer vaccines[J].Int J Cancer,2003,106(6):817-820.
3Tacken P J,de Vries I J,Torensma R,et al.Dendritic-cell immunotherapy:from ex vivo loading to in vivo targeting[J].Nat Rev Immunol,2007,7(10):790-802.
4Brinkman J A,Fausch S C,Weber J S,et al.Peptide-based vaccines for cancer immunotherapy[J].Expert Opin Biol Ther,2004,4(2):181-198.
5Walden P,Sterry W.New and emerging vaccination strategies for prevention and treatment of dermatological diseases[J].Expert Rev Vaccines,2004,3(4):421-431.
6Longley D B,Johnston P G.Molecular mechanisms of drug resistance[J].J Pathol,2005,205(2):275-292.
7Wang S,Yang D,Lippman M E.Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists[J].Semin Oncol,2003,30(Suppl 16):133-142.
8Zhang J,Bowden G T.Targeting Bcl-X(L) for prevention and therapy of skin cancer[J].Mol Carcinog,2007,46 (8):665-670.
9Kim R,Emi M,Tanabe K,et al.Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy[J].Cancer,2004,101(11):2491-2502.
10Walensky L D,Kung A L,Escher I,et al.Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix[J].Science,2004,305(5689):1466-1470.
6Vong Q P, Cao K, Li H Y, et al. Chromosome alignment and segregation regulated by ubiquitination of Survivin [ J ]. Science ,2005,310 ( 5753 ) : 1499-1504.
7Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins [ J ] Nature, 2005,437 ( 7057 ) : 369-375.
8Bowen A R, Hanks A N, Murphy K J,et al. Proliferation,apoptosis,and Survivin expression in keratinocytic neoplasms and hyperplasias[ J]. Am J Dermatopathol,2004,26(3) :177-181.
9Shankar S L,Mani S,O'Guin K N,et al. Survivin inhibition induces human tumor cell death through caspcase-independent and-dependent pathways [J].J Nearoche ,2001,92 (2) :426-429.
10Kenney D M, Geschwindt R D, Kary M R,et al. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary Survivin [ J ]. Tumor Biol, 2007,28 (2) :57-62.
4Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas ( Apo-1/CD95 ) ligand : implications for tumor immune escape [ J ]. Science, 1996,274 ( 529 ) : 1363- 1366.
5Ryan A E, Shanahan F, OConnell J, et al. Fas ligand promotes tumor immune evasion of colon cancer in vivo [ J ]. Cancer Biol, 2006,5(3) :246-249.
6Takahama Y, Yamada Y, Emoto K, et al. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas [ J ]. Gastric Cancer, 2002,5(2) :61-68.
7Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3^+ T regulatory cells show strong prognostic significance in colorectal cancer [ J ]. J Clin Oncol, 2009,27 ( 2 ) : 186-192.
8Aptsiauri N, Carretero R, Garcia Lora A, et al. Regressing and progressing metastatic lesions: resistance to immunotherapy is .predetermined by irreversible HLA class I antigen alterations [ J ]. Cancer Immunol Immunother, 2008,57 ( 11 ) : 1727-1733.
9Shimura T, Suehiro T, Suzuki H, et al. Peptides derived from a soluble molecule of the human leukocyte antigen (HLA) class I cause apoptosis in gastric cancer cell lines [J]. Dig Dis Sci, 2009,54(1 ) :63-69.
10Inoue S, Nakase H, Matsuura M, et al. The effect of proteasome in- hibit MG132 on experimental inflammatory bowel disease[J]. Clin Exp Immunol, 2009,156(1) : 172-182.
